$ABBV News
Last published 3d ago
- 3d agoABBVAllergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 MedicationsPR Newswire– HARMONY IN DIVERSITY is the first study of combined neurotoxin and filler treatment in adults on glucagon-like peptide-1 (GLP-1) medications. In this Phase 4...
- 1w agoGMABABBVMRKJNJ+4A little-known biotech’s high-stakes cancer bet just paid off and its shares doubledCNBCGenmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
- 1w agoABBVAbbVie Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoABBVAbbVie Reports Third-Quarter 2026 Financial ResultsPR NewswireReports Third-Quarter Diluted EPS of $2.37 on a GAAP Basis, an Increase of Over 100.0 Percent; Adjusted Diluted EPS of $3.82, an Increase of Over 100.0 Percent; These Results Include an Unfavorable Impact of $0.11 Per
- 2w agoABBVThe Countdown Is On: BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18PR NewswireThe holiday celebrates personalized treatment with BOTOX® Cosmetic across four FDA-approved aesthetic indication areas, the one and only of its kind in the United States.1BOTOX® Cosmetic Day marks the biggest offer of
- 2w agoABBVAllergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX® Cosmetic (onabotulinumtoxinA)PR NewswireSince its inception, The Confidence Collective has supported more than 500 women entrepreneurs and awarded more than $1.5 million in grants to fuel business growth and empower confidence.In 2026 alone, BOTOX® Cosmetic
- 2w agoABBVAbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple MyelomaPR Newswire– Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can potentially support treatment across a broad range of settings, including in
- 2w agoABBVAllergan Aesthetics Celebrates Eight Years of Engaging Girls in STEM Through Continued Partnership with Girls Inc.PR NewswireAllergan Aesthetics and Girls Inc. continue their commitment to expanding mentorship, education and career exploration opportunities for girls nationwide.A STEM-focused workshop in San Antonio will bring together 20
- 2w agoABBVU.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's DiseasePR NewswireNow with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatmentIn the pivotal Phase 3
- 2w agoABBVApproval of Skyrizi, Bla #761262FDA Approved DrugsApproval Date: 10/23/2026; Drug Name: Skyrizi, Bla #761262; Active Ingredients: RISANKIZUMAB-RZAA; Company: Abbvie Inc; Submission Status: Approval; Application Number: 761262
- 2w agoABBVApproval of Skyrizi, Bla #761105FDA Approved DrugsApproval Date: 10/23/2026; Drug Name: Skyrizi, Bla #761105; Active Ingredients: RISANKIZUMAB-RZAA; Company: Abbvie Inc; Submission Status: Approval; Application Number: 761105
- 2w agoABBVAbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis SuppurativaPR NewswireIn the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo1Lutikizumab met 8 ranked secondary endpoints,
- 3w agoABBVAllergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ EvidencePR NewswireAllergan Aesthetics will present eight scientific posters featuring new and long-term evidence across HArmonyCa™, JUVÉDERM®, SKINVIVE™ and BOTOX® CosmeticThe latest HArmonyCa™ data reinforces its dual-action technology,
- 3w agoABBVAbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology CommunityPR NewswireMulti-year, purpose-driven campaign connects McLaren's on-track performance with support for global patient advocacy organizations serving people living with immune-mediated diseasesThrough the partnership, AbbVie
- 3w agoABBVAbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's DiseasePR NewswireIn a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7 monotherapy at Week 12, the primary endpoint. The treatment
- 3w agoABBV/C O R R E C T I O N - AbbVie/PR NewswireIn the news release, AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio, issued 18-Oct-2026 by AbbVie over PR
- 3w agoABBVSKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026PR Newswire20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programsLatest long-term and real-world data with SKYRIZI®(risankizumab) and RINVOQ®
- 4w agoABBVApproval of Canasa, Nda #021252 (Labeling)FDA Approved DrugsApproval Date: 10/14/2026; Drug Name: Canasa, Nda #021252; Active Ingredients: MESALAMINE; Company: Abbvie; Submission Status: Approval; Submission Classification: Labeling; Application Number: 021252
- 4w agoABBVAbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's DiseasePR NewswireHigher rates of endoscopic remission and ulcer-free endoscopy were observed following subcutaneous SKYRIZI® (risankizumab-rzaa)treatment versus placeboiResults build on previously reported week 12 findings in which
- 1mo agoABBVNew SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel DiseasePR NewswireNew Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and observed subgroups New
- 1mo agoABBVAbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLCPR NewswireAbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted two Breakthrough Therapy Designations (BTDs) for...
- 1mo agoABBVGMABAbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell LymphomaPR NewswireAbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed...
- 1mo agoGMABABBVGenmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell LymphomaBusiness WireEPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline
- 1mo agoABBVAbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental VitiligoPR NewswireAbbVie (NYSE: ABBV) today announced late-breaking results from the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies of RINVOQ® (upadacitinib; 15 mg...
- 1mo agoABBVAbbVie to Host Third-Quarter 2026 Earnings Conference CallPR NewswireAbbVie (NYSE: ABBV) will announce its third-quarter 2026 financial results on Friday, October 30, 2026, before the market opens. AbbVie will host a...
- 1mo agoABBVAbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026PR NewswireAbbVie (NYSE: ABBV) today announced that detailed results from the multiple ascending dose (MAD) part of its Phase 1 study evaluating ABBV-295 will...
- 1mo agoABBVAbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026PR NewswireAbbVie (NYSE: ABBV) today announced that the primary results from the ongoing Phase 2 APEX Part B Dose-Regimen-Finding Study, evaluating...
- 1mo agoABBVAbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV CongressPR NewswireAbbVie (NYSE: ABBV) today announced new research across its diverse dermatology portfolio to be presented at the 2026 European Academy of Dermatology ...
- 1mo agoABBVAbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical DevelopmentPR NewswireAbbVie (NYSE: ABBV) is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI...
- 1mo agoABBVU.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's DiseasePR NewswireAbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only...
- 1mo agoABBVApproval of Juvmo, Nda #220415 (Type 1 - New Molecular Entity)FDA Approved DrugsApproval Date: 09/25/2026; Drug Name: Juvmo, Nda #220415; Active Ingredients: TAVAPADON; Company: Abbvie Inc; Submission Status: Approval; Submission Classification: Type 1 - New Molecular Entity; Application Number: 220415
- 1mo agoABBVAllergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation ApproachPR NewswireAllergan Aesthetics, an AbbVie company (NYSE: ABBV), the global industry leader in aesthetics, today announced the U.S. launch of AA Signature™....
- 1mo agoABBVAbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic ArthritisPR NewswireAbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg tablet and weight-based 1 mg/mL oral...
- 1mo agoABBVAbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug DiscoveryPR NewswireAbbVie (NYSE: ABBV) and Iambic, a clinical-stage life sciences and technology company developing novel medicines through its AI-driven discovery and...
- 1mo agoABBVAbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026PR NewswireAbbVie (NYSE: ABBV) today presented new VRAYLAR® (cariprazine) data at Psych Congress 2026 in New Orleans, including results from two prospective...
- 1mo agoABBVAbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) MeetingPR NewswireAbbVie (NYSE: ABBV) announced today that new data from its broad multiple myeloma research portfolio will be featured at the 23rd International...
- 1mo agoABBVAllergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss MedicationsPR NewswireAllergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced results from two single-center clinical studies evaluating targeted skincare...
- 1mo agoABBVAbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health CampaignPR NewswireAbbVie (NYSE: ABBV), a global pharmaceutical leader, and the PGA TOUR today announced a partnership naming AbbVie the Official Pharmaceutical Sponsor ...
- 1mo agoABBVAllergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin SummitPR NewswireAllergan Aesthetics, an AbbVie company (NYSE: ABBV), will bring its scientific leadership to the 2026 Science of Skin Summit (SSS), taking place Sept....
- 2mo agoABBVApproval of Kybella, Nda #206333 (Labeling)FDA Approved DrugsApproval Date: 09/11/2026; Drug Name: Kybella, Nda #206333; Active Ingredients: DEOXYCHOLIC ACID; Company: Abbvie; Submission Status: Approval; Submission Classification: Labeling; Application Number: 206333
- 2mo agoABBVAbbVie Declares Quarterly DividendPR NewswireThe board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share. The cash dividend is payable November ...
- 2mo agoABBVAbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual MigrainePR NewswireAbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3 LUNA study, which evaluated atogepant, a calcitonin gene-related...
- 2mo agoABBVAbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple MyelomaPR NewswireAbbVie (NYSE: ABBV) announced positive topline results from the Phase 3 CERVINO study1 evaluating etentamig, an investigational BCMA x CD3 bispecific ...
- 2mo agoABBVAPGEAbbVie Completes Acquisition of Apogee TherapeuticsPR NewswireAbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE). With completion of the...
- 2mo agoABBVAbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare ConferencePR NewswireAbbVie (NYSE: ABBV) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026. Management will...
- 2mo agoCNXUESTAEOLSINMD+1A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to CapturePR NewswireEquity Insider News Commentary - The global medical aesthetics market has quietly become one of the most durable growth stories in healthcare....
- 2mo agoABBVSkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare OfferingsPR NewswireAllergan Aesthetics, an AbbVie company (NYSE: ABBV), expands SkinMedica's portfolio of regenerative skincare products with the launch of Barrier...
- 2mo agoABBVAbbVie to Present at the Wells Fargo 21st Annual Healthcare ConferencePR NewswireAbbVie (NYSE: ABBV) will participate in the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026. Management will...
- 2mo agoABBVAbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's DiseasePR NewswireAbbVie (NYSE: ABBV) today announced that it has submitted an application to the European Medicines Agency (EMA) seeking approval for SKYRIZI®...
- 2mo agoABBVAbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer PipelinePR NewswireAbbVie (NYSE: ABBV) today announced new data highlighting research programs across its lung cancer portfolio being presented at the 2026 World...